Gas Storage Denmark: Call for Interest
12.7.2023 13:42:00 EEST | Business Wire | Press release
With its CO2RYLUS project Gas Storage Denmark A/S (GSD) intends to establish onshore CO2 storage at the Stenlille facility – and expects to offer both injection and storage capacity for CO2 from ultimo 2025. The rate of expansion of GSD’s CO2 capacities will depend on customer demand. GSD would therefore appreciate feedback from potential customers with regards to such storage needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230712819960/en/
Stenlille facility in Denmark onshore CO2 storage (Photo: Business Wire)
Companies with an interest in storing CO2 at Stenlille are therefore encouraged to write to co2rylus@gasstorage.dk to inform GSD about their interest. All inquiries will be treated with confidentiality. GSD expects to be open for input from market actors until at least the 15th of August 2023.
About the CO2RYLUS project
The CO2-project in Stenlille is known under the name CO2RYLUS. Based on continuous investigation of the reservoir the expectations to the storage capacity is a minimum of 10 million tons of CO2.
Gas Storage Denmark has 30+ years of experience with underground storage in Stenlille due to the existing methane gas storage facility. Thus, GSD has extensive knowledge of the underground and thorough practical experience with safety and monitoring.
Since the beginning of operations in Stenlille GSD has maintained good relations with neighbors, local stakeholders and communities through active dialogue and transparency regarding plans for development.
Further, the existing infrastructure and organization enables a relatively fast establishment of large-scale CO2-storage in Stenlille.
Finally, an important factor in establishing a CO2 storage adjacent to the existing methane storage operation in Stenlille is the acceleration factor. With this project, Gas Storage Denmark seek to actively work together with the partners in the industry to reduce risks, optimize setup and improve the timelines for CCS projects in Denmark in general.
The CO2RYLUS project intends to create a platform for innovation and acceleration of the CCS technology in Denmark. The platform will be used to disseminate and share technical reservoir knowledge as well as experience with early industry standards in the integrated value chain “from chimney to underground” to promote accelerated development of the industry.
Specifically for this purpose Gas Storage Denmark is hosting and contributing actively to several research projects in collaboration with universities and others.
For further information and/or a show of interest please contact us at: co2rylus@gasstorage.dk
Find the Co2rylus project at: www.gasstorage.dk/co2-storage
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712819960/en/
Contact information
Ann Marker
co2rylus@gasstorage.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom